Tag: amyloidosis research consortium

Rare disease day takes place on February 28th each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients. (more…)

Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)

Finding the best amyloidosis care is not easy, so in 2017 ARC created My Amyloidosis Pathfinder (MAP) to help you discover, learn about, and contact treatment centers and clinical trials that are right for you. Now MAP can do even more. (more…)

The 2018 annual meeting of the American Society of Hematology (ASH) featured the latest scientific updates, including advances in treatment and new insights in amyloidosis. (more…)

The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)